Jasper Therapeutics Q3 2026 Results: Net Loss of $144M, Loss Widens
Jasper Therapeutics reported a significant net loss of $148.4 million for the nine months ended September 30, 2026, primarily driven by a $129.5 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity through a financing and acquisition, ending the period with $135.3 million in cash and cash equivalents.
- Key figure
- Net loss $144M